title: The effect of a donor's history of active substance on outcomes following orthotopic heart transplantation.
abstract: OBJECTIVE
  To review the short-term and long-term outcomes of using heart donors with a history of substance abuse.
  
  
  METHODS
  Retrospective chart review was performed of heart recipients over an 8-year span. Charts provided demographics, mechanisms of donor death, and history of substance abuse. Additionally, charts were quarried for post-operative echocardiography and coronary angiogram results, serologic tests, and survival.
  
  
  RESULTS
  Between January 1997 and December 2005, 689 heart transplants were performed, 150 (21.8%) had a history positive for substance abuse. The mean donor age was 34.5 years (range 16-62 years); most common cause of death was traumatic head injury in 87 donors (58.0%). Most patients (76.0%) had a history of 1 ppd smoking for > or =5 years, 89 (59.3%) had a history of inhaled drug use, 75 (50.0%) alcohol abuse, and 12 (8.0%) intravenous drug use. At a mean follow-up of 8.3 days, 68 hearts (45.3%) had normal, 36 (24.0%) mild, 23 (15.3%) moderate, and 10 (6.7%) severe ventricular dysfunction by echocardiography. Furthermore, 110 hearts (73.3%) had normal coronaries, 20 (13.3%) had mild, and 2 (1.3%) had evidence of moderate coronary artery disease (CAD) on coronary angiogram at a mean follow-up of 9.8 months (range 0.1-43.7 months). All recipients who received organs from known hepatitis B, or C positive, donors converted to positive serologies. Overall post-transplant survival for the group was 89.8% at a mean follow up of 43.3 months (range 5.8-108.6 months).
  
  
  CONCLUSIONS
  A history of donor substance abuse does not have a negative impact on overall survival, cardiac function, risk of transplant associated coronary artery disease (TCAD). In patients who receive organs from virus positive donors, the risk of viral conversion is high, but survival seems not to be influenced.
authors.affiliation: Case Western Reserve School of Medicine, Cleveland, OH, United States.
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Shea
authors.forename: Nikolai A
authors.initials: NA
authors.lastname: Sopko
authors.forename: Kristin
authors.initials: K
authors.lastname: Ludrosky
authors.forename: Katherine
authors.initials: K
authors.lastname: Hoercher
authors.forename: Nicholas G
authors.initials: NG
authors.lastname: Smedira
authors.forename: David O
authors.initials: DO
authors.lastname: Taylor
authors.forename: Randall C
authors.initials: RC
authors.lastname: Starling
authors.forename: Gonzalo V
authors.initials: GV
authors.lastname: Gonzalez-Stawinski
mesh_terms: D000293:Adolescent; D000328:Adult; D017023:Coronary Angiography; D003327:Coronary Disease / Q000209:etiology; D018562:Disease Transmission, Infectious; D006085:Graft Survival; D016027:Heart Transplantation / Q000009:adverse effects / Q000401:mortality; D019694:Hepatitis B, Chronic / Q000635:transmission; D019698:Hepatitis C, Chronic / Q000635:transmission; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D019966:Substance-Related Disorders; D014019:Tissue Donors / Q000523:psychology*; D009927:Tissue and Organ Procurement / Q000379:methods; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000209:etiology
chemical_list: D007166:Immunosuppressive Agents